Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
Trial details
- Registry ID
- NCT07220252
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisNCT07220252 | TGTX | Phase 2, Phase 3 | Recruiting | 2030-01-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |